Strategies for lung cancer patients with KRAS mutations and EGFR-TKI resistance are limited, and it is imperative to develop new EGFR-TKI sensitizers and combination strategies to overcome resistance to EGFR-TKIs. The gene discussed is KRAS; the disease is lung carcinoma.